Alpha 2.0
Login Register
» Authors » Anna Maroto

Anna Maroto

Explore the profile of Anna Maroto including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 29
Followers 0
Related Specialties
Gynecology & Obstetrics
General Medicine
Molecular Biology
Top 10 Co-Authors
Elena Carreras
Manel Mendoza
Pablo Garcia-Manau
Angels Vives
Eva Lopez-Quesada
Erika Bonacina
Lourdes Martin
Mireia Teixidor
Monica Lopez
Marta Ricart
Published In
Acta Obstet Gynecol Scand
J Matern Fetal Neonatal Med
JAMA
Sci Data
Am J Med Genet A
Affiliations
Soon will be listed here.
Recent Articles
1.
Evaluation of an Alternative Screening Method for Gestational Diabetes Diagnosis During the COVID-19 Pandemic (DIABECOVID STUDY): An Observational Cohort Study
Casellas A, Martinez C, Amigo J, Ferrer R, Marti L, Merced C, et al.
Diagnostics (Basel) . 2025 Jan; 15(2). PMID: 39857074
To evaluate the impact of applying alternative diagnostic criteria for gestational diabetes mellitus (GDM) during the COVID-19 pandemic on GDM prevalence, obstetrical and perinatal outcomes, and costs, as compared to...
2.
Angiogenic factors versus fetomaternal Doppler for fetal growth restriction at term: an open-label, randomized controlled trial
Garcia-Manau P, Bonacina E, Martin-Alonso R, Martin L, Palacios A, Sanchez-Camps M, et al.
Nat Med . 2025 Jan; PMID: 39775039
Small fetuses, with estimated fetal weight (EFW) below the tenth percentile, are classified as fetal growth restriction (FGR) or small for gestational age (SGA) based on prenatal ultrasound. FGR fetuses...
3.
A benchmark for 2D foetal brain ultrasound analysis
Cabezas M, Diez Y, Martinez-Diago C, Maroto A
Sci Data . 2024 Aug; 11(1):923. PMID: 39181905
Brain development involves a sequence of structural changes from early stages of the embryo until several months after birth. Currently, ultrasound is the established technique for screening due to its...
4.
Placental growth factor at 24-28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trial
Ricart M, Bonacina E, Garcia-Manau P, Lopez M, Caamina S, Vives A, et al.
Acta Obstet Gynecol Scand . 2024 Aug; 103(11):2273-2280. PMID: 39171611
Introduction: This study aims to evaluate the safety of discontinuing aspirin treatment at 24-28 weeks in women at high risk after first-trimester combined screening for preeclampsia (PE) and normal placental...
5.
Novel variant in ACTA1 identified in a fetus with akinesia deformation sequence and cortical development delay
Martinez-Diago C, Mademont-Soler I, Bonmati A, Rodo C, Alberch A, Obon M, et al.
Prenat Diagn . 2024 Apr; 44(8):996-998. PMID: 38666792
We present a case of fetal akinesia deformation sequence due to nemaline myopathy (NM). In addition to the muscle manifestations, prenatal observations included an enlarged subarachnoid space and delayed cortical...
6.
Clinical effectiveness of routine first-trimester combined screening for pre-eclampsia in Spain with the addition of placental growth factor
Garcia-Manau P, Bonacina E, Serrano B, Caamina S, Ricart M, Lopez-Quesada E, et al.
Acta Obstet Gynecol Scand . 2023 Oct; 102(12):1711-1718. PMID: 37814344
Introduction: Pre-eclampsia affects 2%-8% of pregnancies and is one of the leading causes of maternal and perinatal morbidity and mortality. First-trimester screening using an algorithm that combines maternal characteristics, mean...
7.
Mid-trimester uterine artery Doppler for aspirin discontinuation in pregnancies at high risk for preterm pre-eclampsia: Post-hoc analysis of StopPRE trial
Bonacina E, Garcia-Manau P, Lopez M, Caamina S, Vives A, Lopez-Quesada E, et al.
BJOG . 2023 Aug; 131(3):334-342. PMID: 37555464
Objective: To assess whether aspirin treatment can be discontinued in pregnancies with normal uterine artery pulsatility index (≤90th percentile) at 24-28 weeks. Design: Post-hoc analysis of a clinical trial. Setting:...
8.
Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial
Mendoza M, Bonacina E, Garcia-Manau P, Lopez M, Caamina S, Vives A, et al.
JAMA . 2023 Feb; 329(7):542-550. PMID: 36809321
Importance: Aspirin reduces the incidence of preterm preeclampsia by 62% in pregnant individuals at high risk of preeclampsia. However, aspirin might be associated with an increased risk of peripartum bleeding,...
9.
The Fetal Growth Restriction at Term Managed by Angiogenic Factors Versus Feto-Maternal Doppler (GRAFD) Trial to Avoid Adverse Perinatal Outcomes: Protocol for a Multicenter, Open-Label, Randomized Controlled Trial
Garcia-Manau P, Mendoza M, Bonacina E, Martin-Alonso R, Martin L, Palacios A, et al.
JMIR Res Protoc . 2022 Oct; 11(10):e37452. PMID: 36222789
Background: Fetal smallness affects 10% of pregnancies. Small fetuses are at a higher risk of adverse outcomes. Their management using estimated fetal weight and feto-maternal Doppler has a high sensitivity...
10.
Gestational age-based reference ranges for cervical length and preterm birth prediction in triplet pregnancies: an observational retrospective study
Rodo C, de la Calle M, Maroto A, Maiz N, Arevalo S, Garcia-Manau P, et al.
BMC Pregnancy Childbirth . 2022 Aug; 22(1):669. PMID: 36042432
Objectives: To develop gestational age-based reference ranges for cervical length in triplet pregnancies. The secondary objective was to assess the performance of cervical length measured between 18 and 20 + ...